
How moving from the U.S. to Costa Rica's ‘blue zone' transformed this family's life forever
When Kema Ward-Hopper and her then-fiance Nicholas Hopper, both from the U.S., decided to get married in Costa Rica, they had no idea that they'd end up relocating there a few years later.
But a series of devastating events led the couple and daughter Aaralyn, now 15, to a new life in the Central American country's very own 'blue zone,' one of the regions of the world where people live longest and are the healthiest.
Ward-Hopper, a health and life coach, was diagnosed with breast cancer a few months before their wedding in 2016.
'[I had] started treatment and everything,' Ward-Hopper tells CNN Travel. 'If you see pictures from my wedding, I didn't have hair, and I didn't really look like myself. But I was sick.'
Special place
While she hadn't been feeling well before they travelled to Costa Rica for their big day, Ward-Hopper noticed a change in her energy levels during the time that they spent there.
'I just felt the best that I had been feeling since I'd been diagnosed,' she says. 'When we got back.
'That feeling good… I thought that I was getting better. But it really seemed like it was environmental, because after about a week, I was feeling bad again.
'So that was the first indicator that there was something special about Costa Rica.'
Ward-Hopper went on to have a unilateral mastectomy before undergoing reconstruction surgery and the family, who were based in Houston, Texas, tried to return to normal.
However, they suffered another major blow when their home was destroyed by a Category 4 hurricane in August 2017.
'I had the surgery and then Hurricane Harvey hit Houston,' she says. 'And we ended up losing our home. So it just seemed like a lot of bad things [happening] back to back to back to back.'
After struggling to find a new home, the couple realized that there wasn't anything holding them to Houston anymore, and decided that it was time to move on.
'My husband was like, 'Well, let's just leave the country,' adds Ward-Hopper.
They initially mulled over relocating to four potential destinations – Ghana, Sweden, Mexico, and of course, Costa Rica.
'Costa Rica ended up winning out over the other places that were on our list,' adds Ward-Hopper, explaining that they were impressed by the country's health care and education system, as well as the environmental protections in place – Costa Rica is the first tropical country to have reversed deforestation.
'Ever since we left there from our honeymoon, we just felt like we wanted to get back there and just feel good,' she adds. There's something energetic about being in Costa Rica.'
'Serendipitous' move
Ward-Hopper goes on to explain that the country's proximity to the U.S. – Costa Rica is less than four hours from Houston by plane, was a major factor in their decision.
'It just felt so serendipitous,' she says. 'I feel like if we had chosen one of the other locations, we would have done way more research and preparation than we did for Costa Rica.'
In 2018, around eight months after deciding to make Costa Rica their new home, the family left Houston to start afresh in Pueblo Nuevo, a neighbourhood located in the Nicoya Peninsula, one of the world's blue zones, along with Loma Linda in California, Italy's Sardinia, Japan's Okinawa and Greece's Ikaria.
'My husband and I came first and we were here for six weeks without my daughter,' says Ward-Hopper, explaining that they'd signed a lease on a property a friend had found for them.
'It was like a second honeymoon.'
The couple spent their time tending to their garden, meeting the locals and getting used to their new surroundings.
'We were in the jungle,' she says, recalling how they had to adapt to the sounds and creatures that came with their new environment.
'It was an adventure. My memory of that time is very fond. By the time we came back with our daughter, it was peak rainy season. So that was a whole adventure in and of itself.'
As they'd entered Costa Rica on a tourist visa, the couple were only permitted to remain in the country for 90 days at a time, and would regularly return to the U.S. to renew their visas.
Thankfully, Ward-Hopper already spoke Spanish before they arrived, while her daughter had some knowledge of the language, which helped the family to transition more quickly.
'I don't know that we would have gotten some of the deals that we've gotten had we not had the ability to communicate,' she says, adding that her husband, who runs a logistics business, has been learning Spanish during their time there.
As the family settled into life in Costa Rica, Ward-Hopper, who describes their first year in the country as 'one long learning experience,' was particularly struck by the country's strong sense of community.
'I had an idea of what I thought community was, but that was completely obliterated when I got here and experienced true community,' she says.
'The locals were helpful whether they knew you or not… It was amazing. The community really looked out for each other.'
New addition
According to Ward-Hopper, Aaralyn adapted very quickly and enjoyed being able to spend so much time on the beach and going on 'lots of hikes.'
'My husband and I both commented that she was able to kind of have a childhood like we had in the 80s and 90s,' she says.
'Being able to go outside and play outside of the watchful eye of your parents.'
The family also found that they felt more energized, which Ward-Hopper attributes to access to fresh fruit, vegetables and whole foods, as well as cleaner air.
'The health benefits of the blue zone, I think, show up later in life,' she says.
'But we have noticed that we feel better when we're here. Our cardiac health and lung health seems to be better.'
In August 2019, Ward-Hopper learned that she was pregnant with her second child.
'It was a weird turn of events,' she admits. 'I didn't expect to get pregnant.'
When the global Covid-19 pandemic hit in 2020, shutting down much of the world, the family were granted permission to remain in Costa Rica on their tourist visas.
Ward-Hopper welcomed her son Nicolai at their home in Pueblo Nuevo in April 2020.
Aside from not being able to have extended family with her due to border restrictions, she says that giving birth in Costa Rica turned out to be a wonderful experience.
'The birth of my son was kind of like a meditation,' she adds. 'Everything was so intentional… I wish I could have had the experience with my daughter.'
Sadly, Ward-Hopper's sister passed away suddenly a few months later.
Due to the complications around border restrictions at the time and the fact that Nicolai was born in Costa Rica and would have been unable to leave at that stage, Ward-Hopper made the difficult decision not to return to the U.S. to be with her family.
'That was also a really hard point in our journey,' she says, before recounting the way the local community rallied around them to make sure that they 'felt loved and supported.'
'That's the kind of community that we live in,' she adds.
The family of four, who have since moved to a larger house in Nicoya, are now settled in Costa Rica and their lives couldn't be more different than they were in Houston.
For Ward-Hopper, one of the best things about the Costa Rican lifestyle is the way in which children are embraced in pretty much every aspect of everyday life.
'I feel like in the States, you feel pressure taking your young child out to dinner or something,' she says.
'Here, if your kid wants to play and walk around the table, then they tell you to leave them alone and let them. So it's just different.
Family first
'They love children. And I don't necessarily know that I felt the same when my daughter was little.
'It's a very family oriented nation. Families definitely [come] first.'
Ward-Hopper, who has been 'cancer free' for several years, has adapted to a slower paced lifestyle and learned to not 'be so uptight.'
'In the U.S., everything is super fast,' Ward-Hopper says, noting that she's had to learn to stop apologizing every time she's a few minutes late.
'You know the saying, 'If you're on time, you're late.' But here, that is not the case.'
The average life expectancy in Nicoya is said to be around 85 years and the region has a number of centenarians.
'They're [the centenarians] delightful to talk with,' Ward-Hopper says, noting that she's always touched to see the way in which the local families take care of each other, with the old taking care of the young, and the young taking care of the old.
'The elderly are a part of caring for the youngest generation – their grandchildren, or their great grandchildren, because they're in such good shape,' she says.
'And it's that way because they're hardworking people, and they walk a lot of the places and they eat really well.
'So I think all of those things contribute to their long life. They also live with the land and not in spite of the land.
'So they don't try to remove all of the nature so that they can exist. They just kind of exist with the nature. At least where we live.'
While Ward-Hopper says that there are endless benefits to living in Costa Rica, she stresses that it's not necessarily more affordable than the U.S.
'Costa Rica is the most expensive country in Latin America,' she says. 'But I also think that depends on how you're trying to live.'
Ward-Hopper points out that the cost of living in areas of the country where there is a 'high ratio of expats to locals' is probably around the same as the U.S.
'Where we live, it would be way more expensive, [to have the same] quality of life living back in Houston,' she says.
'So for us it is more affordable, it's getting more expensive as more people move to Costa Rica.
'But there are still places you can go and live cheaper. But it's far away from the most popular spots.'
Even after several years of living in the country, Ward-Hopper says she's still as amazed by its incredible nature as she was in the beginning.
'I'm so grateful, because I was worried that all this will become just the norm,' says Ward-Hopper. 'But it hasn't yet… We're still seeing new creatures this many years in. So that's fun.'
Ward-Hopper and her husband and daughter all became permanent residents of Costa Rica after the birth of Nicolai, who is a Costa Rican citizen.
Although they have no desire to return to the US, Ward-Hopper misses her 'friends, family, and Amazon,' and yearns for a traditional US winter every once in a while.
'When Christmas rolls around, sometimes I just want to put on fuzzy socks and a big hoodie and curl up somewhere cozy with a mug of hot chocolate while it's cold outside,' she says. 'But that does not happen [here]. It's a hot Christmas.'
And while they're happy to stay where they are for the time being, the family don't necessarily plan to remain in Costa Rica indefinitely.
'I think Costa Rica will be [our] home base, but we do have plans to travel and experience other parts of the world,' Ward-Hopper adds, explaining that they're considering spending time in Colombia and Brazil.
'I guess we're more nomadic than stationary, but Costa Rica feels like home.'
By Tamara Hardingham-Gill, CNN
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
2 days ago
- Globe and Mail
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer. It will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for individuals undergoing treatment for breast cancer.


CTV News
30-07-2025
- CTV News
Idylwylde event raises funds for breast cancer
A total of 144 women took part in an annual fundraiser Tuesday at the Idylwylde in Sudbury to raise money for breast cancer research.


Globe and Mail
23-07-2025
- Globe and Mail
KISQALI Achieves Significant Market Growth, Strengthening Its Position in Breast Cancer and CDK4/6 Inhibitors Segment
KISQALI is a promising CDK4/6 inhibitor used in combination with aromatase inhibitors for the treatment of HR-positive, HER2-negative breast cancer. Its market potential remains strong, driven by its efficacy in prolonging progression-free survival in early and metastatic stages of the disease. With a growing demand for targeted therapies and increasing patient awareness, KISQALI's market is expected to expand further. DelveInsight's ' KISQALI Market Size, Forecast, and Market Insight Report ' highlights the details around KISQALI, a cyclin-dependent kinase (CDK4/6 inhibitor). The report provides product descriptions, patent details, and competitor products (marketed and emerging therapies) of KISQALI. The report also highlights the historical and forecasted sales from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Novartis' KISQALI (ribociclib) Overview KISQALI (ribociclib) is a targeted cyclin-dependent kinase inhibitor, a type of drug that helps slow cancer progression by blocking two proteins, cyclin-dependent kinase 4 and 6 (CDK4/6). When these proteins are overactive, they can cause cancer cells to grow and divide too quickly. By specifically targeting CDK4/6, KISQALI aims to prevent cancer cells from replicating uncontrollably. KISQALI was developed by Novartis in collaboration with Astex Pharmaceuticals. In addition to its FDA approval for early breast cancer (EBC) patients in the US, KISQALI is undergoing regulatory reviews in other regions, including the EU and China. KISQALI has received approval for treating metastatic breast cancer (MBC) in 99 countries, including the US and EU. In the US, it is approved for adults with HR+/HER2- advanced or MBC in combination with an aromatase inhibitor (AI) as initial endocrine therapy (ET) or fulvestrant as initial ET or after disease progression. In the EU, it is approved for women with HR+/HER2- advanced or MBC in combination with an AI or fulvestrant as initial ET or after disease progression. In pre- or peri-menopausal women, the ET should be combined with a luteinizing hormone-releasing hormone agonist. In the context of MBC, KISQALI has consistently shown significant overall survival benefits in three Phase III trials. The NCCN Guidelines for breast cancer recommend KISQALI (ribociclib) as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment in HR+/HER2- patients when combined with an AI, making KISQALI the preferred first-line treatment in the US for this patient group. Additionally, KISQALI received the highest score among CDK4/6 inhibitors on the ESMO Magnitude of Clinical Benefit Scale, scoring five out of five for first-line treatment of pre-menopausal patients with HR+/HER2- advanced breast cancer. KISQALI, when combined with either letrozole or fulvestrant, earned a four out of five rating for post-menopausal patients with HR+/HER2- advanced breast cancer in the first-line setting. KISQALI Dosage and Administration The suggested KISQALI dosage is 600 mg (equivalent to three 200 mg film-coated tablets) taken orally once a day for 21 consecutive days, followed by a 7-day break from treatment, making a full cycle of 28 days. KISQALI can be taken with or without food. When used in combination with KISQALI, the recommended dose of fulvestrant is 500 mg, administered on Days 1, 15, 29, and then once a month thereafter. KISAQALI at a Glance Drug Name: KISQALI (ribociclib) Molecule type: Small molecule Developer: Novartis Primary Indication: HR+/HER2− breast cancer Mechanism of action: Cyclin-dependent kinases 4 and 6 inhibitor Route of administration: Oral CDK4/6 inhibitors are a type of targeted cancer therapy that work by blocking the function of cyclin-dependent kinases 4 and 6—enzymes crucial for regulating the cell cycle, particularly the progression from the G1 to S phase, where cells begin DNA replication. By inhibiting these kinases, the drugs effectively stop cancer cell proliferation, leading to growth arrest and potentially cell death. This precise mechanism makes them especially effective in treating hormone receptor-positive, HER2-negative breast cancers, among other types. The introduction and approval of CDK4/6 inhibitors have significantly reshaped the treatment approach for HR+/HER2− metastatic breast cancer. Currently, three main selective CDK4/6 inhibitors, IBRANCE (palbociclib), KISQALI (ribociclib), and VERZENIO (abemaciclib), are commonly used in combination with endocrine therapy as the first-line treatment. Notably, the NCCN now recommends KISQALI as the preferred first-line option for metastatic cases. Once endocrine and targeted therapies no longer work, chemotherapy and antibody-drug conjugates (ADCs) are typically used. IBRANCE remains the market leader among CDK4/6 inhibitors, with around 70% of U.S. patients receiving it when prescribed a drug in this class. Looking ahead, there is strong potential to extend the use of CDK4/6 inhibitors beyond HR+/HER2− advanced breast cancer. According to DelveInsight, market growth in the 7MM is expected to be fueled by rising cancer incidence, greater awareness and access to treatment, and an active pipeline of new indications. Emerging Competitors of KISQALI Some of the CDK4/6 inhibitors in the pipeline include Lerociclib (G1 Therapeutics and Pepper Bio), Atirmociclib (Pfizer), PRT3645 (Prelude Therapeutics), Trilaciclib (G1 Therapeutics), SPH4336 (Shanghai Pharma Biotherapeutics), Dalpiciclib (Jiangsu Hengrui Pharmaceuticals), BGB-43395 (BeiGene), BTX-9341 (Biotheryx), and Euthare-155008 (Shengke Pharmaceuticals), among others. In May 2024, G1 Therapeutics and Pepper Bio announced a global licensing agreement (excluding Asia-Pacific) for lerociclib, a selective CDK4/6 inhibitor. Using their COMPASS platform, Pepper Bio identified CDK4/6 as key targets for Hepatocellular carcinoma, with preclinical models showing superior efficacy. Lerociclib is now advancing to Phase II trials. Key Milestones of KISQALI In December 2024, Novartis shared updated findings from the pivotal Phase III NATALEE trial of KISQALI, highlighting its prolonged effectiveness even after treatment ends when used alongside endocrine therapy (ET). The results demonstrated a 28.5% sustained reduction in the risk of distant recurrence (HR=0.715; 95% CI 0.604–0.847; nominal P<0.0001) compared to ET alone in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC). In November 2024, Novartis announced that the European Commission (EC) had approved KISQALI, in combination with an aromatase inhibitor (AI), for use as adjuvant treatment in patients with HR-positive HER2-negative early breast cancer who are at high risk of recurrence. In September 2024, Novartis announced that the FDA has approved KISQALI, in combination with an aromatase inhibitor (AI), for adjuvant treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) who are at high risk of recurrence — including individuals with node-negative (N0) disease. In September 2020, Novartis proudly shared that KISQALI received the highest possible score—five out of five—on the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale (ESMO-MCBS) for use as a first-line treatment in premenopausal patients with hormone receptor-positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer. In July 2018, Novartis received a new approval from the FDA for KISQALI (ribociclib) to treat women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced or metastatic breast cancer. In March 2017, the FDA approved KISQALI, in combination with an aromatase inhibitor, as a first-line endocrine-based treatment for postmenopausal women with hormone receptor-positive, HER2-negative (HR+/HER2−) advanced or metastatic breast cancer. Discover how KISQALI CDK4/6 inhibitor is shaping the breast cancer treatment landscape @ KISQALI Cost KISQALI Market Dynamics KISQALI (ribociclib) is a CDK4/6 inhibitor used primarily in the treatment of HR-positive, HER2-negative breast cancer. Since its approval in 2017 by the FDA, it has become a key player in the competitive oncology market. The drug works by inhibiting cyclin-dependent kinases 4 and 6, which are responsible for the progression of many cancers, including breast cancer. KISQALI is typically used in combination with aromatase inhibitors or letrozole, offering a therapeutic advantage by enhancing anti-tumor efficacy while also maintaining manageable safety profiles. The market dynamics for KISQALI are heavily influenced by the broader competitive landscape of CDK4/6 inhibitors, with notable competitors including IBRANCE (palbociclib) and VERZENIO (abemaciclib). These drugs are all vying for market share in a segment that is expected to grow significantly due to increasing breast cancer diagnoses and the demand for targeted therapies. KISQALI has carved a niche for itself with favorable clinical trial data, including its ability to deliver improved progression-free survival rates, which is appealing to oncologists and healthcare providers. However, pricing pressures, especially in markets with significant healthcare budget constraints, and the rising popularity of combination therapies will influence KISQALI's market position in the coming years. Additionally, ongoing research and the potential for new indications could further shape KISQALI's growth trajectory. Table of Contents 1. Report Introduction 2. KISQALI: Novartis 2.1. Product Overview 2.2. Other Development Activities 2.3. Clinical Development 2.4. Clinical Trials Information 2.5. Safety and Efficacy 2.6. Product Profile 2.7. Market Assessment 2.7.1. The 7MM Analysis 2.7.1.1. Cost Assumptions and Rebate 2.7.1.2. Pricing Trends 2.7.1.3. Analogue Assessment 2.7.1.4. Launch Year and Therapy Uptake 2.7.2. The United States Market Analysis 2.7.3. EU4 and the United Kingdom Market Analysis 2.7.3.1. Germany 2.7.3.2. France 2.7.3.3. Italy 2.7.3.4. Spain 2.7.3.5. UK 2.7.4. Japan Market Analysis 2.8. Market Drivers 2.9. Market Barriers 2.10. SWOT Analysis 3. Key Cross of Marketed Competitors of KISQALI 4. Key Cross of Emerging Competitors of KISQALI Related Reports CDK4/6 Inhibitor Market CDK4/6 Inhibitor Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CDK4/6 inhibitor companies, including Pfizer, Prelude Therapeutics, G1 Therapeutics, Pepper Bio, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Sandeep Joshi Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website: